More than 239,200 patients aged 12 years or older with moderate-to-severe atopic dermatitis (AD) and children aged 6–11 years old with severe AD have been prescribed DUPIXENT worldwide as of July 20212




*After the initial dose, the dosing may be increased to 200 mg Q2W in patients with body weight of 15 kg to less
than 60 kg based on physician’s assessment.1

 

Children
15 to <60kg

Children
≥60kg

Adolescents
<60 kg

Adolescents & all adults
≥60 kg

Pre-filled syringe

Pre-filled pen

Self-administration

HCP/caregiver administered

Dosing frequency

Q4W/Q2W

Q2W

Q2W

Q2W

 

DUPIXENT can be self-injected or administrated by a caregiver/HCP via a pre-filled pen or syringe for adults
and adolescent1

For children aged 6–11 years old, DUPIXENT can only be administered by a caregiver via a pre-filled syringe
after appropriate training by a HCP1

There is weight-based dosing for adolescents (12 years and older) with moderate-to-severe AD and for
children (6–11 years old) with severe AD1

DUPIXENT can now be administered with a pre-filled pen for patients aged 12 years and older1

Learn how to administer DUPIXENT using the single-use, pre-filled pen.1


How to store DUPIXENT1


Keep the pre-filled pen(s) or syringe(s) and all medicines out of the reach of children1

Keep unused pre-filled pens or syringes in the original carton and store in the refrigerator between 2°C and 8°C1

Store pre-filled pens or syringes in the original carton to protect it from light1

Do not keep pre-filled pens or syringes at room temperature (<25oC) for more than 14 days1

Do not shake the pre-filled pen or syringe at any time1

Do not heat the pre-filled pen or syringe1

Do not freeze the pre-filled pen or syringe1

 

Do not place the pre-filled pen or syringe into direct sunlight1

 



To find out more about how to administer DUPIXENT or if you would like further information please visit the Resources Section for helpful guides.


Mode of action DUPIXENT

Have questions about how DUPIXENT works?





Find out more


Reimbursement

Learn about the reimbursement of DUPIXENT.





Find out more


Safety Profile

Learn more about safety profile of DUPIXENT.






Find out more

    AD, atopic dermatitis; HCP, healthcare professional; Q2W, once every two weeks; Q4W,  once every four weeks.

    References

    1. DUPIXENT Summary of Product Characteristics. September 2021.
    2. Sanofi Data on File. MAT-IE-2000837 (v3.0).

MAT-IE-2101030(v4.0) | Date of preparation: February 2022